While we cannot with certainty define the mode of action for HDAC3 in the regulation of systemic adiposity, our findings clearly establish that inhibiting intestinal HDAC3 has the capacity for therapeutic utility in the treatment of obesity and metabolic co-morbidities. The gene discussed is HDAC3; the disease is obesity due to melanocortin 4 receptor deficiency.